![[ L to R ]Mr. Rohan Ganapathy, Co-Chairman, CII National Committee on Space; Mr. Mallavarapu Apparao, Chairman, CII National Committee on Space; Ms. Jaya Choraria, Deputy Trade Commissioner for South Asia, UK; H.E. Mr. Antonio Bartoli, Ambassador of Italy to India; Dr. Pawan Goenka, Chairman, IN-SPACe; Dr V. Narayanan, Secretary, Department of Space; Chairman, Space Commission; and Chairman, ISRO; Mr. Shashwat Goenka, Vice President, CII; H.E. Mr. Philip Green OAM, High Commissioner of Australia to India; Mr. ISHII Yasuo, Senior Vice President, JAXA; Mr. Radha Krishnan A, Chairman and Managing Director, NSIL](https://24x7newsworld.com/wp-content/uploads/2026/09/Screenshot-2026-09-08-at-20-52-52-DSC_6125.JPG-JPEG-Image-6048-×-4024-pixels-—-Scaled-14_-360x180.avif){kind=tracking}
Bagsværd, Denmark, 21 September 2026 – Novo Nordisk is today hosting a Capital Markets Day (CMD) in London, where the company is providing an update to its Corporate strategy and strategic ambitions for 20301.
During the day, Novo senior management presentations will cover Corporate strategy, R&D strategy, where to play and how to win across therapy areas, Commercial strategy in the US and International Operations, Global Manufacturing & Supply and Financials.
Key highlights of the strategic ambitions for 20301 are:
Grow and diversify pipeline
- Launch >5 multi-blockbusters by 2030 and deliver >150 bDKK2 pipeline sales in 2035
- ≥5 Phase 3 programmes in obesity and diabetes3
- ≥5 Phase 3 programmes in other TAs3
Drive sustainable growth
- Deliver 2026-30 revenue CAGR in line with industry peers1
- Scale capacity to be able to serve 10x more people with obesity on oral GLP-1
- Serve >60m patients globally by 2030
Deliver attractive returns
- Maintain a broadly stable operating margin1
- Maintain an attractive dividend per share
All sessions of the CMD are webcast live, and a replay will be made available in the investor section of novonordisk.com. Presentation material from the CMD will also be available throughout the day in the investor section of novonordisk.com.
Novo is the global healthcare company that believes lasting health starts now. For over a century, we’ve combined leading scientific expertise with a deep understanding of people’s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, approximately 66,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we’re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. says release.
